JSPR250117P10000
- 1.03
- +0.17+19.77%
Jasper Therapeutics Newsroom
RBC Capital Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $68
Analysts Conflicted on These Healthcare Names: Neurocrine (NBIX), Vertex Pharmaceuticals (VRTX) and Jasper Therapeutics (JSPR)
Jasper Therapeutics Initiated at Outperform by BMO Capital
Jasper Therapeutics Analyst Ratings
BMO Capital Initiates Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $63
Stifel Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80
RBC Capital Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $68
Oppenheimer Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80
A Quick Look at Today's Ratings for Jasper Therapeutics(JSPR.US), With a Forecast Between $60 to $70
Promising Outlook for Jasper Therapeutics: Buy Rating Reinforced by Advancements in Briquilimab
Oppenheimer Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80
JMP Securities Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $70
H.C. Wainwright Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $65
Capital One Financial Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $55
JMP Securities Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $70
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR) and Coherus Biosciences (CHRS)
Stifel Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $80
JMP Securities Reiterates Market Outperform on Jasper Therapeutics, Maintains $70 Price Target
A Quick Look at Today's Ratings for Jasper Therapeutics(JSPR.US), With a Forecast Between $55 to $90
Jasper Therapeutics Analyst Ratings